
OPRX
USDOptimizeRx Corporation Common Stock
即時價格
價格圖表
關鍵指標
市場指標
開盤
$18.900
最高
$19.383
最低
$18.689
交易量
0.42M
公司基本面
市值
356.4M
行業
Health Information Services
國家
United States
交易統計
平均交易量
0.37M
交易所
NCM
貨幣
USD
52週範圍
AI分析報告
最後更新: 2025年10月30日OPRX Analysis: Navigating OptimizeRx's Volatile Growth Path
Recent Price Movements
- July-August Transition: Shares jumped 37% on August 8 (12.84→17.30) with volume 5x average
- September Rally: Steady climb from 17.16 (Sept 2) to 20.51 (Sept 29) - 19.5% gain
- Current Position: Trading at $20.56 (Oct 29) after hitting $22.25 weekly high
- Pattern Alert: 3 failed attempts to hold above $22 since late September
Key Catalysts
- October 10 Analyst Boost: JMP Securities raised target to $23 (+15% from current)
- AI Prediction Signals:
- Short-term projections: +1.1% (D1), +1.7% (D2), +2.5% (D3)
- High-confidence bullish signal (81.1% AI confidence)
- Volume Surges: 3 recent spikes (584k on Aug 28, 662k on Sept 29, 421k on Oct 24)
Strategic Considerations
Strengths
- Explosive revenue growth (55.2% YoY)
- Strong institutional interest (4.9x average volume days)
- Healthcare tech positioning in growing sector
Concerns
- Profitability challenges (Negative ROE: -8.2%)
- Heavy debt load (24.29 Debt/Equity ratio)
- Technical resistance at $22 level
Actionable Insights
- Entry Window: Current price ($20.56) near support level ($20.55)
- Trade Parameters:
- Stop Loss: $18.48 (10% downside protection)
- Take Profit: $22.50 (9.4% upside)
- Alternative Entries: $20.64-$21.08 range
- Holding Strategy: 1-2 week horizon aligns with AI predictions
Final Perspective
OptimizeRx presents a high-growth opportunity tempered by financial health concerns. The combination of analyst upgrades, AI bullishness, and technical support near current levels creates a favorable risk/reward scenario for short-term traders. Long-term investors should monitor debt management and profitability improvements.
Disclaimer: This analysis references historical data and AI predictions that may not reflect future performance. Consult a financial advisor before making investment decisions. Past performance does not guarantee future results.
相關新聞
JMP Securities Maintains Market Outperform on OptimizeRx, Raises Price Target to $23
JMP Securities analyst Constantine Davides maintains OptimizeRx with a Market Outperform and raises the price target from $20 to $23.
AI預測Beta
AI推薦
更新於: 2025年11月4日 下午05:09
65.0% 信心度
風險與交易
入場點
$19.62
獲利了結
$20.97
止損
$17.52
關鍵因素
相關股票
保持更新
設定價格提醒,獲取AI分析更新和即時市場新聞。